162 related articles for article (PubMed ID: 15547747)
1. Utility of initial MRI for predicting extent of residual disease after neoadjuvant chemotherapy: analysis of 70 breast cancer patients.
Murata Y; Ogawa Y; Yoshida S; Kubota K; Itoh S; Fukumoto M; Nishioka A; Moriki T; Maeda H; Tanaka Y
Oncol Rep; 2004 Dec; 12(6):1257-62. PubMed ID: 15547747
[TBL] [Abstract][Full Text] [Related]
2. Histologic breast cancer extent after neoadjuvant chemotherapy: comparison with multidetector-row CT and dynamic MRI.
Tozaki M; Uno S; Kobayashi T; Aiba K; Yoshida K; Takeyama H; Shioya H; Tabei I; Toriumi Y; Suzuki M; Kawakami M; Fukuda K
Radiat Med; 2004; 22(4):246-53. PubMed ID: 15468945
[TBL] [Abstract][Full Text] [Related]
3. MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer.
Goorts B; Dreuning KMA; Houwers JB; Kooreman LFS; Boerma EG; Mann RM; Lobbes MBI; Smidt ML
Breast Cancer Res; 2018 Apr; 20(1):34. PubMed ID: 29669584
[TBL] [Abstract][Full Text] [Related]
4. Preoperative evaluation of residual tumor extent by three-dimensional magnetic resonance imaging in breast cancer patients treated with neoadjuvant chemotherapy.
Akazawa K; Tamaki Y; Taguchi T; Tanji Y; Miyoshi Y; Kim SJ; Ueda S; Yanagisawa T; Sato Y; Tamura S; Noguchi S
Breast J; 2006; 12(2):130-7. PubMed ID: 16509837
[TBL] [Abstract][Full Text] [Related]
5. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.
An YY; Kim SH; Kang BJ
World J Surg Oncol; 2017 Nov; 15(1):198. PubMed ID: 29110671
[TBL] [Abstract][Full Text] [Related]
6. Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implications.
Zhou J; Li G; Sheng F; Qiao P; Zhang H; Xing X
Acta Radiol; 2016 May; 57(5):529-37. PubMed ID: 26231950
[TBL] [Abstract][Full Text] [Related]
7. Effective factors to raise diagnostic performance of breast MRI for diagnosing pathologic complete response in breast cancer patients after neoadjuvant chemotherapy.
Choi BB; Kim SH
Acta Radiol; 2015 Jul; 56(7):790-7. PubMed ID: 24951616
[TBL] [Abstract][Full Text] [Related]
8. [Value of dynamic contrast-enhanced MRI in assessment of early response to neoadjuvant chemotherapy in breast cancer].
Wang XH; Peng WJ; Xin C; Tan HN; Gu YJ; Tang F; Mao J
Zhonghua Zhong Liu Za Zhi; 2010 Jul; 32(7):539-43. PubMed ID: 21029700
[TBL] [Abstract][Full Text] [Related]
9. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
[TBL] [Abstract][Full Text] [Related]
10. [Performances of breast magnetic resonance imaging in the context of neoadjuvant chemotherapy for breast cancer to predict pathological complete response].
Brisson C; Diguisto C; Vildé A; Body G; Arbion F; Leveque J; Ouldamer L
J Gynecol Obstet Hum Reprod; 2017 Feb; 46(2):147-154. PubMed ID: 28403971
[TBL] [Abstract][Full Text] [Related]
11. A new histological therapeutic classification system to predict eradicated and residual lymph nodes in breast cancer after neoadjuvant chemotherapy.
Morohashi S; Yoshizawa T; Seino H; Hirai H; Haga T; Ota R; Wu Y; Yoshida E; Hakamada K; Kijima H
Oncol Rep; 2016 May; 35(5):2592-8. PubMed ID: 26935647
[TBL] [Abstract][Full Text] [Related]
12. Comparison of
Hunt KN; Conners AL; Goetz MP; O'Connor MK; Suman V; Kalari K; Weinshilboum R; Wang L; Carter J; McLaughlin S; Aspitia AM; Gray R; Northfelt D; Boughey JC
AJR Am J Roentgenol; 2019 Oct; 213(4):932-943. PubMed ID: 31166752
[No Abstract] [Full Text] [Related]
13. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
14. Imaging response and residual metastatic axillary lymph node disease after neoadjuvant chemotherapy for primary breast cancer.
Hieken TJ; Boughey JC; Jones KN; Shah SS; Glazebrook KN
Ann Surg Oncol; 2013 Oct; 20(10):3199-204. PubMed ID: 23846781
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of MRI for treatment response assessment after taxane- and anthracycline-based neoadjuvant chemotherapy in HER2-negative breast cancer.
Charehbili A; Wasser MN; Smit VT; Putter H; van Leeuwen-Stok AE; Meershoek-Klein Kranenbarg WM; Liefers GJ; van de Velde CJ; Nortier JW; Kroep JR
Eur J Surg Oncol; 2014 Oct; 40(10):1216-21. PubMed ID: 25150151
[TBL] [Abstract][Full Text] [Related]
16. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy.
Belli P; Costantini M; Malaspina C; Magistrelli A; LaTorre G; Bonomo L
Clin Radiol; 2006 Nov; 61(11):946-53. PubMed ID: 17018307
[TBL] [Abstract][Full Text] [Related]
17. Clinical usefulness of AJCC response criteria for neoadjuvant chemotherapy in breast cancer.
Keam B; Im SA; Lim Y; Han SW; Moon HG; Oh DY; Cho N; Lee SH; Han W; Moon WK; Kim DW; Kim TY; Park IA; Noh DY
Ann Surg Oncol; 2013 Jul; 20(7):2242-9. PubMed ID: 23529780
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
Kang DK; Kim TH; Han TS; Kim KS; Yim H
J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
[TBL] [Abstract][Full Text] [Related]
19. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of DCE-MRI for early evaluation of pathological complete response to neoadjuvant chemotherapy in resectable primary breast cancer: A single-center prospective study.
Sun YS; He YJ; Li J; Li YL; Li XT; Lu AP; Fan ZQ; Cao K; Ouyang T
Breast; 2016 Dec; 30():80-86. PubMed ID: 27652977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
